Improving Alzheimer's disease phase II clinical trials

Barry Greenberg, María C. Carrillo, J. Michael Ryan, Michael Gold, Kim P. Gallagher, Michael Grundman, Robert Berman, T. Ashwood, Eric Siemers

Type: Article

Publication Date: 2012-11-16

Citations: 28

DOI: https://doi.org/10.1016/j.jalz.2012.02.002

View Publication

Locations

Alzheimer s & Dementia - View
PubMed - View

Similar Works

Action	Title	Year	Authors
+	Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions	2019	David R. Elmaleh Martin R. Farlow Peter S. Conti Ronald G. Tompkins Ljiljana Kundakovic Rudolph E. Tanzi
+ PDF Chat	The need for thorough phase II studies in medicines development for Alzheimer’s disease	2015	Julian Gray David Fleet Bengt Winblad
+	Translational Medicine Strategies in Alzheimer's Disease Drug Development	2019	Veronika Logovinsky
+ PDF Chat	Biomarkers for the Early Stages of Clinical Development in Alzheimer’s Disease	2010	Régis Bordet Jean‐François Dartigues Bruno Dubois Jean‐Marie Goehrs Laura Vernoux Franck Semah Florence Pasquier C. Bidaut‐Mazel Zeina Antoun Arnaud Olivier
+	Landscape of Phase II Trials in Alzheimer’s Disease	2023	Alina Lee Di Shan David Castle Tarek K. Rajji Clement Ma
+ PDF Chat	Alzheimer's Disease Drug Development Targets Disease Modification	2015	MITCHEL L. ZOLER
+	Disease-Modifying Therapies for Alzheimer’s Disease	2013	Joshua D. Grill Jeffrey L. Cummings
+ PDF Chat	Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future	2018	Jeffrey L. Cummings Aaron Ritter Kate Zhong
+	Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force	2013	Bruno Vellas María C. Carrillo Cristina Sampaio H. Robert Brashear Eric Siemers Harald Hampel Lon S. Schneider Michael W. Weiner Rachelle S. Doody Zaven S. Khachaturian
+	IS ALZHEIMER’S DISEASE DRUG DEVELOPMENT BROKEN? WHAT MUST BE IMPROVED	2014	P.J. Ousset Jeffrey L. Cummings Julien Delrieu Victor Legrand Niels D. Prins Bengt Winblad J. Touchon M W Weiner Bruno Vellas
+	Challenges and potential of optimal design in late phase clinical trials through application in Alzheimer’s disease	2014	Sebastian Ueckert Marilee Andrew Mats O. Karlsson Kaori Ito Brian Corrigan Andrew C. Hooker
+ PDF Chat	What lessons can be learned from failed Alzheimer’s disease trials?	2015	Jeremy H. Toyn
+ PDF Chat	[P2–034]: ARE ALZHEIMER's DRUG FAILURES DUE TO INACTIVE COMPOUNDS OR ARE WE DOING SOMETHING WRONG?	2017	Suzanne Hendrix Noel Ellison
+	Achieving Inclusion in Pharmacological Clinical Trials for Alzheimer’s Disease	2024	Doris P Molina‐Henry Rema Raman
+	FUTILITY ANALYSES IN ALZHEIMER’S DISEASE (AD) CLINICAL TRIALS: A RISKY BUSINESS	2020	Paul Aisen Rema Raman
+	AD clinical trials: The challenges of the past and present; the hope for the future	2015	Roger Clarnette
+	Disease Modifying Trials in Alzheimer's Disease: Perspectives for the Future	2008	Bruno Vellas Nicola Coley Sandrine Andrieu
+	Optimizing phase II of drug development for disease‐modifying compounds	2008	Jeffrey L. Cummings
+	Phase 1 Trials in Alzheimer’s Disease Drug Development	2022	Manfred Windisch
+ PDF Chat	Value-Generating Exploratory Trials in Neurodegenerative Dementias	2021	Lauren G. Friedman Nicholas McKeehan Yuko Hara Jeffrey L. Cummings Dawn Matthews Jian Zhu Richard C. Mohs Deli Wang Suzanne Hendrix Melanie Quintana

Works That Cite This (4)

Action	Title	Year	Authors
+	Design of a Bayesian adaptive phase 2 proof‐of‐concept trial for BAN2401, a putative disease‐modifying monoclonal antibody for the treatment of Alzheimer's disease	2016	Andrew Satlin Jinping Wang Veronika Logovinsky Scott Berry Chad J. Swanson Shobha Dhadda Donald A. Berry
+ PDF Chat	Phase II clinical trials of anti-amyloid β antibodies: When is enough, enough?	2017	Michael Gold
+	Prevalence and Impact of Bypassing or Overriding Phase 2 Trials in Neurologic Drug Development	2024	Hannah Moyer Robyn Mellett Karine Vigneault Maya McKeown Jason Karlawish Erika F. Augustine Lon S. Schneider Jonathan Kimmelman
+	Translational Medicine Strategies in Alzheimer's Disease Drug Development	2019	Veronika Logovinsky

Works Cited by This (2)

Action	Title	Year	Authors
+	An Adaptive Optimal Design for the <i>E</i> <sub>max</sub> Model and Its Application in Clinical Trials	2009	Sergei Leonov Sam Miller
+	Hypothesis: A single clinical trial plus causal evidence of effectiveness is sufficient for drug approval	2003	Carl C. Peck